UK Community Advisory Board (UK-CAB)

UK-CAB 66: AIDS 2018 feedback, future ART, cure research

Friday 3 August 2018


09.15-09.30 Arrival, tea and refreshments
09.30-10.00 Welcome and introductions:

UK-CAB updates and company pre-meeting

10.00-11.30 Company meeting: Janssen
11.30-11.45 Break
11.45-12.45 RIVER Cure Study – Dr Sarah Fidler
12.45-14.00 Lunch – @ Marquis Cornwallis pub
14.00-14.45 Future treatments – Damian Kelly
14.45-15.30 AIDS 2018 conference feedback

Garry Brough/Lisa Thorley

15.30-15.45 Break
15.45-17.00 Community rep feedback:

MRC CTU PPI – Ben Cromarty

Discussion of meeting updates

17.00 Meeting close

Slides and meeting report

UK-CAB 66 meeting report Aug 2018 (Word .doc) – confidential, available  to members only

Slides on RIVER study (PDF).

Slides from Janssen presentation (PDF) – confidential, available  to members only

Background reading and videos/webcasts

RIVER study

Future drugs

AIDS 2018 feedback


Financial support

The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year.

This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering. The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.

Companies that develop and market medicines have a responsibility to actively engage with advocacy organisations. HIV positive people and their advocates should also be able to ask manufacturers directly about the safety and efficacy of their products. We should be involved in their proposals for future research.

For a list of companies that support the UK-CAB please see the “about us” page.